Ian Read on M&A strategy
From Pfizer Earnings Conference Call Q2 2018 · · AlphaStreet
“Specifically, at this time, regarding a large or transformative deal, I don't believe we need such a deal to drive the growth of this Company. I would be and I think our leadership team is united on this view, we'd be far better off focusing on developing our pipeline, investing in our pipeline, bringing these products to market, growing these products than undertaking a large deal.”
On , Ian Read, Former Chairman & Chief Executive Officer at Pfizer, spoke about M&A strategy during Pfizer Earnings Conference Call Q2 2018 on AlphaStreet.
About Ian Read
During Pfizer’s second-quarter 2018 earnings call, Chairman and CEO Ian Read discussed the company’s restructuring plans and pipeline outlook. Read stated that effective at the beginning of the 2019 fiscal year, Pfizer would operate three businesses: a science-based innovative medicines business (including biosimilars and a new hospital unit), an off-patent branded and generic established medicines business, and a Consumer Healthcare business. He described this as a natural evolution as the company transitions past 2020. Read also said that through 2022, Pfizer sees potential for approximately 25 to 30 approvals, with up to 15 having blockbuster potential, citing Xeljanz and Xtandi as the first two. Read addressed drug pricing and access, saying it is Pfizer’s job to advocate for affordable access and that the company would continue to work with the president on his blueprint for strengthening the healthcare system. He noted that the secretary’s intention to remove the Safe Harbor for discounts to eliminate rebates would be a positive change for the industry, adding that about 40% of pharmaceutical prices subsidize the rest of the healthcare system. Regarding mergers and acquisitions, Read said he did not believe a large or transformative deal was needed to drive growth, and that the leadership team was united in focusing on developing the pipeline and bringing products to market.